Radicava (edaravone) approved for the treatment of amyotrophic lateral sclerosis.
An intravenous infusion administered daily for 14 days at initiation of treatment, followed by a 14-day drug-free period.
After initiation, Radicava is administered daily for 10 days out of the 14-day cycle, followed by a 14-day rest.
Patients who took Radicava showed less decline on a clinical assessment of daily functioning at 24 weeks compared with participants who received the placebo.
Common adverse reactions include: contusion and gait disturbance, hives, swelling, shortness of breath, and allergic reactions to sodium bisulfite.